Comparative Pharmacology
Head-to-head clinical analysis: XYROSA versus XYWAV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XYROSA versus XYWAV.
XYROSA vs XYWAV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
XYROSA is a fixed-dose combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker. Sacubitril inhibits neprilysin, increasing natriuretic peptides and other vasoactive peptides, leading to vasodilation, natriuresis, and inhibition of fibrosis. Valsartan blocks the angiotensin II type 1 receptor, reducing vasoconstriction, aldosterone release, and cardiac remodeling.
XYWAV (calcium, magnesium, potassium, and sodium oxybates) is a mixture of oxybate salts. The exact mechanism of action is unknown, but it is thought to involve modulation of GABA-B receptors and possibly GHB receptors, leading to increased slow-wave sleep and reduced cataplexy.
1.5 mg/kg IV once weekly; maximum 100 mg per dose.
Oral, starting dose 2.25 g twice nightly, titrated weekly by 0.75 g per dose up to a maximum of 4.5 g twice nightly. Administer first dose at bedtime, second dose 2.5–4 hours later.
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal half-life is approximately 1 hour (range 0.5–1.5 hours) for oxybate (GHB) component; the mixed salts formulation does not alter elimination. Short half-life necessitates twice-nightly dosing for sustained sleep.
Primarily renal excretion of unchanged drug (~60%) and glucuronide metabolite (~30%); biliary/fecal elimination accounts for <10%.
Primarily renal; >95% of the dose is eliminated as metabolites (3-hydroxypropionic acid, 4,5-dihydroxyhexanoic acid) and <5% as unchanged drug via urine. Fecal excretion accounts for <1%.
Category C
Category C
CNS Depressant / Narcolepsy Agent
CNS Depressant / Narcolepsy Agent